PMID- 32957565
OWN - NLM
STAT- MEDLINE
DCOM- 20210518
LR  - 20210518
IS  - 1660-3397 (Electronic)
IS  - 1660-3397 (Linking)
VI  - 18
IP  - 9
DP  - 2020 Sep 17
TI  - 16S rRNA Sequencing and Metagenomics Study of Gut Microbiota: Implications of BDB 
      on Type 2 Diabetes Mellitus.
LID - 10.3390/md18090469 [doi]
LID - 469
AB  - Gut microbiota has a critical role in metabolic diseases, including type 2 
      diabetes mellitus (T2DM). 
      3-bromo-4,5-bis(2,3-dibromo-4,5-dihydroxybenzyl)-1,2-benzenediol (BDB) is a 
      natural bromophenol isolated from marine red alga Rhodomela confervoides. Our 
      latest research showed that BDB could alleviate T2DM in diabetic BKS db mice. To 
      find out whether BDB modulates the composition of the gut microbiota during T2DM 
      treatment, 24 BKS db diabetic mice were randomly grouped to receive BDB (n = 6), 
      metformin (n = 6), or the vehicle (n = 6) for 7 weeks in a blinded manner. 
      Non-diabetic BKS mice (n = 6) were used as normal control. Diabetic mice treated 
      with BDB or metformin demonstrated significant reductions in fasting blood 
      glucose (FBG) levels compared with the vehicle-treated mice in the 7th week. 
      Pyrosequencing of the V3-V4 regions of the 16S rRNA gene revealed the changes of 
      gut microbiota in response to BDB treatment. The result demonstrated short-chain 
      acid (SCFA) producing bacteria Lachnospiraceae and Bacteroides were found to be 
      significantly more abundant in the BDB and metformin treated group than the 
      vehicle-treatment diabetic group. Remarkably, at the genus levels, Akkermansia 
      elevated significantly in the BDB-treatment group. Metagenomic results indicated 
      that BDB may alleviate the metabolic disorder of diabetic mice by promoting 
      propanoate metabolism and inhibiting starch and sucrose metabolism, amino sugar 
      and nucleotide sugar metabolism. In conclusion, our study suggests that the 
      anti-diabetic effect of BDB is closely related to the modulating structure of gut 
      microbiota and the improvement of functional metabolism genes of intestinal 
      microorganisms.
FAU - Zhang, Liang
AU  - Zhang L
AD  - Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese 
      Academy of Sciences, 7 Nanhai Road, Qingdao 266071, China.
AD  - Laboratory for Marine Drugs and Bioproducts of Qingdao, National Laboratory for 
      Marine Science and Technology, Qingdao 266000, China.
AD  - School of Earth and Planetary, University of Chinese Academy of Sciences, Beijing 
      100049, China.
FAU - Luo, Jiao
AU  - Luo J
AD  - School of Public Health, Qingdao University, Qingdao 266071, China.
FAU - Li, Xiangqian
AU  - Li X
AD  - State Key Laboratory of Microbial Technology, Shandong University, 72 Binhai 
      Road, Qingdao 266237, China.
FAU - Guo, Shuju
AU  - Guo S
AD  - Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese 
      Academy of Sciences, 7 Nanhai Road, Qingdao 266071, China.
AD  - Laboratory for Marine Drugs and Bioproducts of Qingdao, National Laboratory for 
      Marine Science and Technology, Qingdao 266000, China.
AD  - School of Earth and Planetary, University of Chinese Academy of Sciences, Beijing 
      100049, China.
FAU - Shi, Dayong
AU  - Shi D
AD  - State Key Laboratory of Microbial Technology, Shandong University, 72 Binhai 
      Road, Qingdao 266237, China.
LA  - eng
GR  - JQ201722/Shandong Provincial Natural Science Foundation for Distinguished Young 
      Scholars/
GR  - 817033540, 81803344/National Natural Science Foundation of China/
GR  - 2017-CXZX01-1-1, 2017-CXZX01-3-9/Taishan scholar Youth Project of Shandong 
      province, Qingdao Marine Biomedical Science and Technology Innovation Center 
      Project/
GR  - U1706213/NSFC-Shan-dong Joint Fund/
GR  - 2019RKE27018/National Program for Support of Top-notch Young Professionals, Key 
      research and development plan (soft science) project of Shandong province/
PT  - Journal Article
DEP - 20200917
PL  - Switzerland
TA  - Mar Drugs
JT  - Marine drugs
JID - 101213729
RN  - 0 (3-bromo-4,5-bis(2,3-dibromo-4,5-dihydroxybenzyl)-1,2-benzenediol)
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Catechols)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Animals
MH  - Bacteria/*drug effects/genetics/growth & development/metabolism
MH  - Benzhydryl Compounds/isolation & purification/*pharmacology
MH  - Biomarkers/blood
MH  - Blood Glucose/*drug effects/metabolism
MH  - Catechols/isolation & purification/*pharmacology
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/microbiology
MH  - Disease Models, Animal
MH  - Gastrointestinal Microbiome/*drug effects/genetics
MH  - High-Throughput Nucleotide Sequencing
MH  - Hypoglycemic Agents/isolation & purification/*pharmacology
MH  - Male
MH  - *Metagenomics
MH  - Mice, Inbred C57BL
MH  - Rhodophyta/chemistry
MH  - *Ribotyping
PMC - PMC7551199
OTO - NOTNLM
OT  - 16S rRNA sequencing
OT  - BDB
OT  - gut microbiota
OT  - marine red alga
OT  - metagenomics
OT  - type 2 diabetes mellitus
COIS- The authors declare no conflict of interest.
EDAT- 2020/09/23 06:00
MHDA- 2021/05/19 06:00
PMCR- 2020/09/01
CRDT- 2020/09/22 01:02
PHST- 2020/08/25 00:00 [received]
PHST- 2020/09/05 00:00 [revised]
PHST- 2020/09/09 00:00 [accepted]
PHST- 2020/09/22 01:02 [entrez]
PHST- 2020/09/23 06:00 [pubmed]
PHST- 2021/05/19 06:00 [medline]
PHST- 2020/09/01 00:00 [pmc-release]
AID - md18090469 [pii]
AID - marinedrugs-18-00469 [pii]
AID - 10.3390/md18090469 [doi]
PST - epublish
SO  - Mar Drugs. 2020 Sep 17;18(9):469. doi: 10.3390/md18090469.